CN110305135B - Pemetrexed disodium intermediate and preparation method thereof - Google Patents

Pemetrexed disodium intermediate and preparation method thereof Download PDF

Info

Publication number
CN110305135B
CN110305135B CN201810227817.0A CN201810227817A CN110305135B CN 110305135 B CN110305135 B CN 110305135B CN 201810227817 A CN201810227817 A CN 201810227817A CN 110305135 B CN110305135 B CN 110305135B
Authority
CN
China
Prior art keywords
stirring
pemetrexed disodium
pyrrolo
dihydro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810227817.0A
Other languages
Chinese (zh)
Other versions
CN110305135A (en
Inventor
臧超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lunnan Better Pharmaceutical Co ltd
Original Assignee
Lunan Pharmaceutical Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunan Pharmaceutical Group Corp filed Critical Lunan Pharmaceutical Group Corp
Priority to CN201810227817.0A priority Critical patent/CN110305135B/en
Publication of CN110305135A publication Critical patent/CN110305135A/en
Application granted granted Critical
Publication of CN110305135B publication Critical patent/CN110305135B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of medicine synthesis, and particularly relates to a pemetrexed disodium intermediate II-1 and a preparation method thereof. 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidine-5-yl) ethyl ] benzoic acid is used as a starting material, and is subjected to acylation reaction in acetic acid and acetic anhydride, and after the reaction is finished, the intermediate II-1 is obtained through treatment. The intermediate II-1 is simple to prepare, protects the amino group to avoid generating an impurity V in the reaction, simultaneously prevents the oxidative discoloration problem caused by the unstable amino group in the reaction process, has mild conditions, high yield and more stable products, and is beneficial to actual production.

Description

Pemetrexed disodium intermediate and preparation method thereof
Technical Field
The invention belongs to the technical field of medicine synthesis, and particularly provides a pemetrexed disodium intermediate 4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidine-5-yl) ethyl ] benzoic acid and a preparation method thereof.
Background
Pemetrexed is an antifolate preparation containing a pyrrole pyrimidine group as a core, and inhibits cell replication by destroying normal metabolic processes of intracellular folate dependence, thereby inhibiting tumor growth. In vitro studies have shown that pemetrexed inhibits the activity of thymidylate synthase, dihydrofolate reductase and glycinamide nucleotide formyltransferase, which are enzymes essential for the synthesis of folic acid, involved in the biological re-synthesis of thymine and purine nucleotides. Pemetrexed disodium is a multi-target antifolate, interferes with the folic acid dependent metabolic process necessary in the cell proliferation process to exert antiproliferative activity, and has activity on various solid tumors. It has been currently approved in europe for the treatment of malignant pleural mesothelioma and non-small cell lung cancer, and in 2004 in the united states for the treatment of malignant pleural mesothelioma.
Pemetrexed has no compound patent in China, and foreign companies apply for preparation patents and composition patents in China, but do not authorize any patent. As a specific medicine for treating malignant pleural mesothelioma and a potential medicine for treating advanced lung cancer, the medicine has been touted by a plurality of pharmaceutical enterprises since the market, and at present, a plurality of domestic pharmaceutical enterprises obtain production lots, so that the market prospect is very good.
The pemetrexed disodium has a complex structure and more synthesis routes, and a well-known and excellent process route is characterized in that 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidine-5-yl) ethyl ] benzoic acid (II) is used as an initial raw material and is condensed, salified and hydrolyzed with L-glutamic acid diethyl ester hydrochloride to obtain the pemetrexed disodium. The synthetic route is as follows:
Figure BDA0001601750950000021
however, the process route has more defects, which are mainly shown in that the starting material pemetrexed for preparing N- {4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoyl } -L-glutamic acid diethyl ester tosylate (with the structure shown in formula III) has more reaction active sites, so that more byproducts are generated, the control is difficult, and particularly, the content of an impurity V (with the structure shown in formula V) is up to 5-10%. In order to meet the quality requirement, the intermediate (with the structure shown in formula III) must be refined for 2-3 times, so that the overall yield is low, the cost is high, and the proportion of the intermediate to the cost of the whole pemetrexed disodium raw material is high.
Figure BDA0001601750950000022
In order to improve the product quality and reduce the cost, the synthesis route 1 is improved and optimized. The method aims to protect the naked amido of the important starting material pemetrexed acid (II) through amidation reaction, thereby avoiding the generation of impurity V, leading the intermediate not to need to be refined, directly carrying out the next reaction, improving the yield by nearly 40 percent, and simultaneously shortening the reaction period.
Disclosure of Invention
In order to solve the problems of low yield, high production cost, instability and low purity of pemetrexed disodium in the prior art, the invention provides a pemetrexed disodium intermediate II-1, a preparation method thereof and a preparation method of pemetrexed disodium IV.
The technical scheme adopted by the invention is as follows:
in one aspect, the invention provides a pemetrexed disodium intermediate II-1 and a preparation method thereof.
The chemical name of the intermediate II-1 is as follows: 4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid, having the formula:
Figure BDA0001601750950000031
the preparation method of the pemetrexed disodium intermediate II-1 comprises the following steps:
4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidine-5-yl) ethyl ] benzoic acid is used as a starting material, and is subjected to acylation reaction in acetic acid and acetic anhydride, and after the reaction is finished, the intermediate II-1 is obtained through treatment.
The reaction route is as follows:
Figure BDA0001601750950000032
specifically, the preparation method of the pemetrexed disodium intermediate II-1 comprises the following steps:
adding 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidine-5-yl) ethyl ] benzoic acid into acetic acid, heating to 30 ℃, stirring for dissolving, dropwise adding acetic anhydride, heating to 40-50 ℃, preserving heat for reacting for 1 hour, decompressing and evaporating the acetic acid, adding pure water, stirring, adjusting the pH value to 5-6 by using a 5% sodium hydroxide solution, crystallizing, filtering, and drying to obtain an intermediate II-1.
Preferably, the molar ratio of 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid to acetic anhydride is 1:1-2, more preferably, the molar ratio is 1: 1.2.
The chemical name of the intermediate I is as follows: l-glutamic acid diethyl ester, the structural formula is as follows:
Figure BDA0001601750950000033
the preparation method of the intermediate I comprises the following steps: taking L-glutamic acid diethyl ester hydrochloride as an initial material, potassium carbonate as a deacidification agent, and dichloromethane as a solvent to carry out deacidification reaction to obtain a light yellow oily intermediate I, namely L-glutamic acid diethyl ester.
The synthetic route is as follows:
Figure BDA0001601750950000041
on the other hand, the invention also provides a preparation method of pemetrexed disodium, which comprises the following steps:
taking the intermediate I and the intermediate II-1 as raw materials, carrying out condensation reaction under the action of N, N-carbonyldiimidazole, then reacting with p-toluenesulfonic acid to obtain an intermediate III-1N- {4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoyl } -L-glutamic acid diethyl ester tosylate, then removing the p-toluenesulfonic acid from the intermediate III-1 in a sodium hydroxide solution, carrying out ester hydrolysis and amide hydrolysis, and then forming sodium salt to obtain pemetrexed disodium.
The synthetic route is as follows:
Figure BDA0001601750950000042
specifically, the preparation method of pemetrexed disodium comprises the following steps:
(1) preparation of intermediate III-1:
adding DMF into the intermediate II-1, stirring and dissolving, adding N, N-carbonyldiimidazole, reacting for 2 hours at 50-60 ℃, adding the intermediate I, heating to 70-80 ℃, reacting for 3 hours, evaporating to dryness under reduced pressure, adding dichloromethane for dissolving, pouring into a mixed solution of pure water and triethylamine, stirring and separating liquid, separating out an organic phase, washing, drying and evaporating to dryness, adding absolute ethyl alcohol, stirring and dissolving, adding p-toluenesulfonic acid, reacting for 1 hour, cooling and crystallizing, performing suction filtration, and drying to obtain an intermediate III-1;
(2) preparation of pemetrexed disodium:
and mixing the intermediate III-1 with a sodium hydroxide solution, dropwise adding a 10% hydrochloric acid solution after complete dissolution to adjust the pH to 2-3, stirring for crystallization, performing suction filtration, adding absolute ethyl alcohol into a filter cake, heating to 50-60 ℃, stirring for dissolution, adjusting the pH to 6-7 with a 20% sodium hydroxide solution, stirring for crystallization, performing hot filtration, adding a 50% sodium hydroxide solution into a filtrate for crystallization, performing suction filtration, and performing vacuum drying to obtain pemetrexed disodium.
Preferably, the mole ratio of the intermediate II-1 to the intermediate (I) is 1:1-2, more preferably 1: 1.2.
Preferably, the mole ratio of the intermediate II-1 to the p-toluenesulfonic acid in the preparation method of the pemetrexed disodium is 1:1-2, more preferably 1: 1.2.
Preferably, the mole ratio of the intermediate II-1 to the N, N-carbonyl diimidazole in the preparation method of pemetrexed disodium is 1: 1.2-2.
The invention has the advantages that:
(1) the intermediate II-1 is simple to prepare, and the amidation reaction is carried out by taking 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidine-5-yl) ethyl ] benzoic acid as a raw material, so that the amino is protected, the impurity V generated by the reaction is avoided, the problem of oxidative discoloration caused by unstable amino in the reaction process is solved, the condition is mild, the yield is high, the product is stable, and the method is favorable for actual production.
(2) The intermediate I and the intermediate II-1 are used as raw materials to prepare the intermediate III-1, because the-NH of the intermediate II-12Protected, avoids the self reaction of the intermediate II-1 to generate an impurity V compound, greatly improves the quality and yield of the intermediate III-1, and greatly reduces the production cost.
(3) The intermediate III-1 is used as a raw material to prepare pemetrexed disodium, deacidification, hydrolysis and salt formation can be completed in an ethanol sodium hydroxide solution, the operation is simple, the condition is mild, special deprotection reaction is not needed, but the amino group is protected, so that the oxidative degradation of the amino group is prevented, the quality and the purity of a final product are greatly improved, and the purity is more than 99.85%.
Detailed Description
The advantageous effects of the present invention will now be further described by the following examples, which are for illustrative purposes only and do not limit the scope of the present invention, and variations and modifications apparent to those of ordinary skill in the art according to the present invention are also included in the scope of the present invention.
Example 1:
preparation of L-glutamic acid diethyl ester:
weighing L-glutamic acid diethyl ester hydrochloride (48g 0.2mol), adding into a 500ml four-mouth bottle, adding 120ml pure water, stirring for dissolving, adding 18g potassium carbonate, reacting for 0.5 hour, adding 100ml dichloromethane, stirring for separating liquid, extracting a water layer with 80ml × 3 pure water for three times, collecting an organic phase, drying, and evaporating to dryness to obtain a product L-glutamic acid diethyl ester (the molar yield is 97.5%, and the purity is 94.3%).
Example 2
Preparation of 4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid:
weighing 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (60g and 0.2mol), adding 200ml acetic acid into a 500ml four-mouth bottle, heating to 30 ℃, stirring and dissolving, dropwise adding acetic anhydride (0.2mol), heating to 40 ℃, keeping the temperature and reacting for 1 hour, drying the acetic acid by evaporation under reduced pressure, adding 300ml pure water, stirring, adjusting the pH to 5 by using a 5% sodium hydroxide solution, stirring and crystallizing for 2 hours, cooling to 0-5 ℃, performing suction filtration, drying to obtain a product 4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (the molar yield is 96.3%, purity 99.2%).
4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2, 3-d)]Pyrimidin-5-yl) ethyl]Mass Spectrometry of benzoic acid [ M-H]+=341.3。
1H-NMR:1H NMR(400MHz,D2O)δ:
12.12(s,1H);8.15(d,1H,J=8.20Hz);8.15(d,1H,J=8.20Hz);7.58(d,1H,J=8.20Hz);7.58(d,1H,J=8.20H z);7.03(d,1H,J=8.26Hz);7.03(d,1H,J=8.26);6.06(s,1H);2.76(m,2H);2.70(m,2H);2.34(m,2H);1.86( s,1H)。
13C-NMR:13C NMR(400MHz,D2O)δ:179.30,169.34,160.08,148.74,148.53,146.68, 130.43,130.43,128.18,128.18,128.91,127.91,117.14,104.97,37.12,29.43,23.10。
Example 3
Preparation of 4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid:
weighing 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (60g and 0.2mol), adding 200ml acetic acid into a 500ml four-mouth bottle, heating to 30 ℃, stirring and dissolving, dropwise adding acetic anhydride (0.4mol), heating to 50 ℃, keeping the temperature and reacting for 1 hour, drying the acetic acid by evaporation under reduced pressure, adding 300ml pure water, stirring, adjusting the pH to 6 by using a 5% sodium hydroxide solution, stirring and crystallizing for 2 hours, cooling to 0-5 ℃, performing suction filtration, drying to obtain a product 4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (the molar yield is 96.9 percent), purity 99.0%).
4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2, 3-d)]Pyrimidin-5-yl) ethyl]Mass spectrum of benzoic acid,1H-NMR、13C-NMR is given in example 2
Example 4
Preparation of 4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid:
weighing 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (60g and 0.2mol), adding 200ml acetic acid into a 500ml four-mouth bottle, heating to 30 ℃, stirring and dissolving, dropwise adding acetic anhydride (0.24mol), heating to 50 ℃, keeping the temperature and reacting for 1 hour, drying the acetic acid by evaporation under reduced pressure, adding 300ml pure water, stirring, adjusting the pH to 6 by using a 5% sodium hydroxide solution, stirring and crystallizing for 2 hours, cooling to 0-5 ℃, performing suction filtration, drying to obtain a product 4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (the molar yield is 97.1 percent), purity 99.5%).
4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2, 3-d)]Pyrimidin-5-yl) ethyl]Mass spectrum of benzoic acid,1H-NMR、13C-NMR is given in example 2
Example 5
Preparation of N- {4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoyl } -L-glutamic acid diethyl ester tosylate:
adding 4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (64.6g and 0.19mol) into a 1L four-mouth bottle, adding 650ml of DMF, stirring and dissolving, heating to 50 ℃, adding 0.228mol of N, N-carbonyl diimidazole, keeping the temperature at 50 ℃ for 2 hours, adding L-glutamic acid diethyl ester (0.19mol), heating to 70 ℃, reacting for 3 hours, evaporating under reduced pressure, adding 800ml of dichloromethane for dissolving, pouring into a mixed solution of 1600ml of pure water and 160ml of triethylamine, stirring and separating to obtain an organic phase, washing 1600ml of pure water multiplied by 2 twice, drying and evaporating to dryness, adding 500ml of anhydrous ethanol, stirring and dissolving, dropwise adding 36g of p-toluenesulfonic acid monohydrate and 200ml of anhydrous ethanol solution under the reflux state, after the addition, the reflux reaction is carried out for 1 hour, the temperature is reduced, the crystallization is carried out, the suction filtration is carried out, and the drying is carried out, thus obtaining the product (the molar yield is 87.0 percent, the purity is 98.9 percent, and the content of the impurity V is 0).
N- {4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ]]Pyrimidin-5-yl) ethyl]Mass spectrum of benzoyl } -L-glutamic acid diethyl ester tosylate: [ M-H ]]-=524.5。
1H-NMR:1H NMR(400MHz,(CD3)2SO)δ:
7.80(d,1H,J=8.26Hz);7.80(d,1H,J=8.26Hz);7.55(m,1H),7.55(m,1H);7.30(d,1H,J=8.28Hz);7.30(d, 1H,J=8.28Hz);7.16(d,1H,J=7.87Hz);7.16(d,1H,J=7.87H);6.52(d,1H,J=2.06Hz);4.43(m,1H);4.09( m,1H);4.09(m,1H);2.93(m,2H);2.93(m,2H);2.44(t,2H,J=7.49Hz,);2.29(s,3H);2.06(m,2H);1.83 (s,3H);1.17(m,3H);1.17(m,3H)。
13C-NMR(400MHz,(CD3)2SO):δ:172.69,172.32,170.32,167.08,157.74,151.06,146.20,144. 98,139.11,138.89,131.70,128.80,128.80,128.68,128.68,127.95,127.95,125.98,125.98,119.53,115. 80,99.48,61.02,60.41,52.45,36.18,27.65,26.17,23.21,21.26,14.54,14.54。
Example 6
Preparation of N- {4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoyl } -L-glutamic acid diethyl ester tosylate:
adding 4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (64.6g and 0.19mol) into a 1L four-mouth bottle, adding 650ml of DMF, stirring and dissolving, heating to 50 ℃, adding 0.38mol of N, N-carbonyldiimidazole, keeping the temperature at 60 ℃ for 2 hours, adding L-glutamic acid diethyl ester (0.38mol), heating to 80 ℃, reacting for 3 hours, evaporating under reduced pressure, adding 800ml of dichloromethane for dissolving, pouring into a mixed solution of 1600ml of pure water and 160ml of triethylamine, stirring and separating to obtain an organic phase, washing 1600ml multiplied by 2 of pure water twice, drying and evaporating to dryness, adding 500ml of anhydrous ethanol, stirring and dissolving, dropwise adding 72g of p-toluenesulfonic acid monohydrate and 200ml of anhydrous ethanol solution under a reflux state, after the addition, the reflux reaction is carried out for 1 hour, and the product is obtained by cooling crystallization, suction filtration and drying (the molar yield is 88.1%, the purity is 98.3%, and the content of the impurity V is 0).
N- {4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ]]Pyrimidin-5-yl) ethyl]Mass spectrum of benzoyl } -L-glutamic acid diethyl ester tosylate,1H-NMR、13C-NMR is given in example 5.
Example 7
Preparation of N- {4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoyl } -L-glutamic acid diethyl ester tosylate:
adding 4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (64.6g and 0.19mol) into a 1L four-mouth bottle, adding 650ml of DMF, stirring and dissolving, heating to 50 ℃, adding 0.38mol of N, N-carbonyldiimidazole, keeping the temperature at 60 ℃ for 2 hours, adding L-glutamic acid diethyl ester (0.48mol), heating to 80 ℃, reacting for 3 hours, evaporating under reduced pressure, adding 800ml of dichloromethane for dissolving, pouring into a mixed solution of 1600ml of pure water and 160ml of triethylamine, stirring and separating to obtain an organic phase, washing 1600ml multiplied by 2 of pure water twice, drying and evaporating to dryness, adding 500ml of anhydrous ethanol, stirring and dissolving, adding 90g of p-toluenesulfonic acid monohydrate and 200ml of anhydrous ethanol solution under a reflux state, after the addition, the reflux reaction is carried out for 1 hour, and the product is obtained by cooling crystallization, suction filtration and drying (the molar yield is 84.7%, the purity is 98.6%, and the content of the impurity V is 0).
N- {4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ]]Pyrimidin-5-yl) ethyl]Mass spectrum of benzoyl } -L-glutamic acid diethyl ester tosylate,1H-NMR、13C-NMR is given in example 5.
Example 8
Preparation of pemetrexed disodium:
weighing 36g of sodium hydroxide, adding into 600ml of pure water, stirring and dissolving, cooling to below 30 ℃, adding N- {4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoyl } -L-glutamic acid diethyl ester tosylate (112.7g and 0.16mol), stirring and dissolving, dropwise adding 10% hydrochloric acid solution after complete dissolution to adjust the pH to 2, stirring and crystallizing, carrying out suction filtration, adding a filter cake into a 1L four-mouth bottle, adding 500ml of absolute ethyl alcohol, heating to 50 ℃, stirring and dissolving, adjusting the pH to 6 with 20% sodium hydroxide solution, stirring and crystallizing, carrying out heat filtration, pouring the filtrate into the bottle, adding 24g of 50% sodium hydroxide solution, stirring and heating to 50 ℃, carrying out a stirring reaction for 1 hour, cooling to 0 ℃, stirring and crystallizing for 5 hours, filtering, and drying in vacuum to obtain white solid pemetrexed disodium (molar yield 81.5%, purity 99.85%).
Mass spectrum of pemetrexed disodium: [ M-2Na-2.5H2O + H]-426.4。
Method for preparing pemetrexed disodium1H-NMR:1H NMR(400MHz,D2O)δ=7.58(d,1H,J=8.20Hz);7.58(d,1H, J=8.20Hz);7.02(d,1H,J=8.26Hz);7.02(d,1H,J=8.26Hz);6.16(s,1H);4.32(dd,1H, J=4.78Hz);2.59(m,2H);2.59(m,2H);2.34(m,2H);2.18(m,1H);2.06(m,1H)。
Method for preparing pemetrexed disodium13C-NMR:13C NMR(400MHz,D2O)δ:182.33,179.10,169.84,160.88, 151.74,150.53,146.58,130.43,128.18,128.18,126.91,126.91,118.14,114.97,98.72, 56.00,35.12,34.32,28.43,26.71。
Example 9
Preparation of pemetrexed disodium:
weighing 36g of sodium hydroxide, adding into 600ml of pure water, stirring and dissolving, cooling to below 30 ℃, adding N- {4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoyl } -L-glutamic acid diethyl ester tosylate (112.7g and 0.16mol), stirring and dissolving, dropwise adding 10% hydrochloric acid solution after complete dissolution to adjust the pH to 3, stirring and crystallizing, carrying out suction filtration, adding a filter cake into a 1L four-mouth bottle, adding 500ml of absolute ethyl alcohol, heating to 60 ℃, stirring and dissolving, adjusting the pH to 7 with 20% sodium hydroxide solution, stirring and crystallizing, carrying out heat filtration, pouring the filtrate into the bottle, adding 24g of 50% sodium hydroxide solution, stirring and heating to 50 ℃, carrying out a stirring reaction for 1 hour, cooling to 0 ℃, stirred and crystallized for 5 hours, filtered by suction and dried in vacuum to obtain white solid (molar yield 82.3 percent and purity 99.86 percent).
Mass spectrometry, 1H-NMR and 13C-NMR of pemetrexed disodium were performed in example 8.
Comparative example 1
Preparation of 4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid:
weighing 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (60g and 0.2mol), adding 200ml acetic acid into a 500ml four-mouth bottle, heating to 30 ℃, stirring and dissolving, dropwise adding acetic anhydride (0.5mol), heating to 50 ℃, keeping the temperature and reacting for 1 hour, drying the acetic acid by evaporation under reduced pressure, adding 300ml pure water, stirring, adjusting the pH to 6 by using a 5% sodium hydroxide solution, stirring and crystallizing for 2 hours, cooling to 0-5 ℃, performing suction filtration, drying to obtain a product 4- [2- (2-acetamido-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (the molar yield is 93.4%), purity 97.6%).
4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2, 3-d)]Pyrimidin-5-yl) ethyl]Mass spectrum of benzoic acid,1H-NMR、13C-NMR is given in example 2
Comparative example 2
Preparation of N- {4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoyl } -L-glutamic acid diethyl ester tosylate:
adding 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid (64.6g and 0.19mol) into a 1L four-mouth bottle, adding 650ml of DMF, stirring and dissolving, heating to 50 ℃, adding 0.38mol of N, N-carbonyldiimidazole, keeping the temperature at 60 ℃ for 2 hours, adding L-diethyl glutamate (0.38mol), heating to 80 ℃, reacting for 3 hours, evaporating to dryness under reduced pressure, adding 800ml of dichloromethane for dissolving, pouring into a mixed solution of 1600ml of pure water and 160ml of triethylamine, stirring and separating to obtain an organic phase, washing 1600ml of pure water by 2 twice, drying and evaporating to dryness, adding 500ml of anhydrous ethanol, stirring and dissolving, dropwise adding 72g of p-toluenesulfonic acid monohydrate and 200ml of anhydrous ethanol solution under a reflux state, after the addition, the reflux reaction is carried out for 1 hour, the temperature is reduced, the crystallization is carried out, the suction filtration is carried out, and the drying is carried out, thus obtaining 87.2g of crude product (the molar yield is 70.1 percent, the purity is 92.3 percent, and the content of the impurity V is 6.52 percent).
Adding 87.2g of the crude product into a three-mouth reaction bottle, adding 350ml of N, N-dimethylformamide, heating to 40-45 ℃, stirring to dissolve, dropwise adding 700ml of absolute ethyl alcohol after complete dissolution, slowly precipitating a solid, cooling to room temperature, stirring to crystallize for 1-2h, filtering to obtain 69.8g of the solid, wherein the yield is 80.0%. The above refining operation was repeated 1 time to obtain 55.4g of a solid (purity: 98.2%, impurity V content: 0.07%).
Comparative example 3
In a four-necked flask, 55.4g of N- {4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoyl } -L-glutamic acid diethyl ester tosylate and 200ml of a 2mol/L sodium hydroxide solution were charged, stirred for 1 hour, adjusted to pH 3 with 0.5mol/L hydrochloric acid solution, and the resulting suspension was heated to 65 ℃ for 2.5 hours while controlling the temperature. Cooling to room temperature, filtering, washing the solid with deionized water to obtain N- (4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidine-5-yl) ethyl ] benzoyl) -L-glutamic acid. Adding the N- (4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoyl) -L-glutamic acid obtained in the previous step and 200ml of 0.5mol/L sodium hydroxide into a four-mouth bottle, stirring for 1 hour, filtering to remove insoluble substances to obtain a transparent solution, adjusting the pH to 8 by using 0.5mol/L hydrochloric acid, heating the obtained solution to 50 ℃, stirring for 30 minutes, cooling to room temperature, adding 300ml of a mixed solvent of ethanol and dimethyl sulfoxide (the volume ratio is 10: 1.8), stirring for 10 minutes, stirring for 2 hours at 0 ℃, filtering, washing a solid by using 60ml of the mixed solvent of ethanol and dimethyl sulfoxide (the volume ratio is 10: 1.8), and carrying out vacuum drying at 50 ℃ for 5 hours to obtain pemetrexed disodium, the yield is 60.9 percent, and the purity is 97.5 percent.
Mass spectrometry, 1H-NMR and 13C-NMR of pemetrexed disodium were performed in example 8.

Claims (10)

1. A pemetrexed disodium intermediate II-1 has a chemical name of: 4- [2- (2-acetylamino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid, having the structure:
Figure DEST_PATH_IMAGE002
2. a process for preparing pemetrexed disodium intermediate ii-1 according to claim 1, comprising the steps of:
4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidine-5-yl) ethyl ] benzoic acid is used as a starting material, and is subjected to acylation reaction in acetic acid and acetic anhydride, and after the reaction is finished, the intermediate II-1 is obtained through treatment.
3. The method for preparing pemetrexed disodium intermediate II-1 according to claim 2, comprising the steps of:
adding 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidine-5-yl) ethyl ] benzoic acid into acetic acid, stirring and dissolving, dripping acetic anhydride, reacting at 40-50 ℃ for 1 hour under heat preservation, evaporating the acetic acid under reduced pressure, adding pure water, stirring, adjusting the pH value to 5-6 by using a 5% sodium hydroxide solution, crystallizing, filtering, and drying to obtain an intermediate II-1.
4. The method for preparing pemetrexed disodium intermediate II-1 according to claim 2 or 3, wherein the molar ratio of 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid to acetic anhydride is 1: 1-2.
5. The method for preparing pemetrexed disodium intermediate II-1 according to claim 2 or 3, wherein the molar ratio of 4- [2- (2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2,3-d ] pyrimidin-5-yl) ethyl ] benzoic acid to acetic anhydride is 1: 1.2.
6. A process for the preparation of pemetrexed disodium comprising the steps of:
taking an intermediate I, L-diethyl glutamate and an intermediate II-1 as raw materials, carrying out condensation reaction under the action of N, N-carbonyl diimidazole, then reacting with p-toluenesulfonic acid to obtain an intermediate III-1, then removing the p-toluenesulfonic acid from the intermediate III-1 in a sodium hydroxide solution, carrying out ester hydrolysis and amide hydrolysis, and then forming sodium salt to obtain pemetrexed disodium;
the structure of the intermediate III-1 is shown as the following formula:
Figure DEST_PATH_IMAGE004
7. the method of preparing pemetrexed disodium according to claim 6, comprising the steps of:
(1) preparation of intermediate III-1:
adding DMF into the intermediate II-1, stirring and dissolving, adding N, N-carbonyldiimidazole, reacting for 2 hours at 50-60 ℃, adding the intermediate I, heating to 70-80 ℃, reacting for 3 hours, evaporating to dryness under reduced pressure, adding dichloromethane for dissolving, pouring into a mixed solution of pure water and triethylamine, stirring and separating liquid, separating out an organic phase, washing, drying, evaporating to dryness, adding absolute ethyl alcohol, stirring and dissolving, adding p-toluenesulfonic acid, reacting for 1 hour, cooling and crystallizing, performing suction filtration, and drying to obtain an intermediate III-1;
(2) preparation of pemetrexed disodium:
mixing the intermediate III-1 with a sodium hydroxide solution, dropwise adding a 10% hydrochloric acid solution to adjust the pH to 2-3 after the intermediate III-1 is completely dissolved, stirring for crystallization, performing suction filtration, adding absolute ethyl alcohol into a filter cake, heating to 50-60 ℃, stirring for dissolution, adjusting the pH to 6-7 with a 20% sodium hydroxide solution, stirring for crystallization, performing heat filtration, pouring the filtrate back into a bottle, adding a 50% sodium hydroxide solution for crystallization, performing suction filtration, and performing vacuum drying to obtain the pemetrexed disodium.
8. The process for preparing pemetrexed disodium according to claim 6 or 7, wherein the molar ratio of intermediate II-1 to intermediate I is 1: 1-2.
9. The process for preparing pemetrexed disodium according to claim 6 or 7, wherein the molar ratio of intermediate II-1 to p-toluenesulfonic acid is 1: 1-2.
10. The process for preparing pemetrexed disodium according to claim 6 or 7, wherein the molar ratio of intermediate II-1 to N, N-carbonyldiimidazole is 1: 1.2-2.
CN201810227817.0A 2018-03-20 2018-03-20 Pemetrexed disodium intermediate and preparation method thereof Active CN110305135B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810227817.0A CN110305135B (en) 2018-03-20 2018-03-20 Pemetrexed disodium intermediate and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810227817.0A CN110305135B (en) 2018-03-20 2018-03-20 Pemetrexed disodium intermediate and preparation method thereof

Publications (2)

Publication Number Publication Date
CN110305135A CN110305135A (en) 2019-10-08
CN110305135B true CN110305135B (en) 2022-02-22

Family

ID=68073319

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810227817.0A Active CN110305135B (en) 2018-03-20 2018-03-20 Pemetrexed disodium intermediate and preparation method thereof

Country Status (1)

Country Link
CN (1) CN110305135B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1055182A (en) * 1989-12-11 1991-10-09 普林斯顿大学托管委员会 N-(pyrrolo-" 2,3-d " pyrimidin-3-yl acyl group)-glutamic acid derivatives
WO1998008382A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
CN102006890A (en) * 2007-12-04 2011-04-06 阿尔尼拉姆医药品有限公司 Targeting lipids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1055182A (en) * 1989-12-11 1991-10-09 普林斯顿大学托管委员会 N-(pyrrolo-" 2,3-d " pyrimidin-3-yl acyl group)-glutamic acid derivatives
WO1998008382A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
CN102006890A (en) * 2007-12-04 2011-04-06 阿尔尼拉姆医药品有限公司 Targeting lipids

Also Published As

Publication number Publication date
CN110305135A (en) 2019-10-08

Similar Documents

Publication Publication Date Title
RU2489435C2 (en) Useful pharmaceutical salts of 7-[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidine-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d] pyrimidine-4-one
CN102911176B (en) Preparation method of pemetrexed disodium
US20110124861A1 (en) Process for Preparing Pemetrexed Disodium and Its Intermediate, 4-(4-Carbomethoxyphenyl) Butanal
TWI609017B (en) Process for the preparation of pemetrexed and lysine salt thereof
CN114040906A (en) Novel preparation method of peramivir trihydrate and water system drying method thereof
CN110305135B (en) Pemetrexed disodium intermediate and preparation method thereof
CN110305134B (en) Pemetrexed disodium intermediate and preparation method thereof
CN105503854A (en) New crystal form substance of Dasatinib anhydrous substance and preparation method thereof
WO2022127327A1 (en) Bosutinib 1,3-propanediether dimer impurity and preparation method therefor
CN112194660B (en) PDE2 inhibitor phenyl pyrazolopyrimidine compound and preparation method thereof
CN113549075A (en) Synthesis method of tofacitinib citrate diastereoisomer impurity
CN111116593B (en) Continuous preparation method of imatinib
CN110343111B (en) Preparation method of tofacitinib citrate
WO2020048343A1 (en) Synthesis method for 6-furfurylaminopurine
CN111471045A (en) Preparation method of tofacitinib impurity
EP2997031A1 (en) Process for the preparation of high purity amorphous pemetrexed disodium and crystalline forms of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid
CN110305136A (en) A kind of pemetrexed disodium intermediate and preparation method thereof
CN110305137A (en) A kind of pemetrexed disodium intermediate and preparation method thereof
JPH0417195B2 (en)
CN112442038B (en) Industrial preparation method of pemetrexed disodium
CN112174970B (en) Method for preparing pemetrexed disodium with high yield
US8952153B2 (en) One pot process for preparing pemetrexed disodium
CN116178376A (en) Synthesis method of Pevonedistit intermediate
CN102093254A (en) Preparation method of 3-(2,2,2-trimethylhydrazine)propionate dihydrate
KR20080062412A (en) Preparation method for 3-amino-9,13b-dihydro-1h-dibenz-[c,f]imidazo[1,5-a]-azepine hydrochloride having improved purity and yield

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221116

Address after: 276006 No. 209 Hongqi Road, Shandong, Linyi

Patentee after: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd.

Address before: 276005 No. 209 Hongqi Road, Shandong, Linyi

Patentee before: LUNAN PHARMACEUTICAL Group Corp.

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: An intermediate of pemetrexed disodium salt and its preparation method

Effective date of registration: 20230117

Granted publication date: 20220222

Pledgee: Industrial and Commercial Bank of China Limited Linyi Shizhong Sub-branch

Pledgor: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd.

Registration number: Y2023980031096